Physician profile
Eric D Wolf
NPI 1023106093
$4,967.81
in general payments reported to CMS, 2019-2025
31 companies · $706 in 2025
The $706 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,211 · 2022: $1,301 · 2023: $972 · 2024: $778 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.57 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $926.00 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $777.92 | 2021-2025 | Breztri, Fasenra, Tezspire |
| Genzyme Corporation | $636.83 | 2021-2025 | |
| Mylan Specialty L.P. | $622.04 | 2021-2024 | Yupelri |
| Csl Behring | $350.74 | 2021-2024 | Hizentra, Haegarda |
| Abbvie INC. | $254.66 | 2021-2025 | |
| Optinose US, INC. | $253.71 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.71 | 2023-2025 | Glassia, Hyqvia, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $125.29 | 2024 | Dupixent |
| Inspire Medical Systems, INC. | $116.51 | 2022 | |
| Genentech USA, INC. | $90.01 | 2021-2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.66 | 2021 | |
| Amgen INC. | $75.37 | 2021-2025 | Tezspire, Repatha |
| Actelion Pharmaceuticals US, INC. | $67.70 | 2021-2022 | |
| Philips North America LLC | $57.26 | 2021-2024 | (Ak6) Vest Therapy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.39 | 2024 | |
| Axsome Therapeutics, INC. | $30.77 | 2024-2025 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $30.41 | 2022 | |
| Almatica Pharma LLC | $28.96 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.73 | 2022 | |
| Pharming Healthcare, INC. | $21.68 | 2022 | |
| Biocryst US Sales Co., LLC | $20.83 | 2021 | |
| Merck Sharp & Dohme LLC | $20.02 | 2022 | |
| Verona Pharma, INC. | $17.95 | 2025 | Ohtuvayre |
| Phadia US INC. | $17.94 | 2024 | Immunocap |
| Grifols USA, LLC | $17.20 | 2022 | |
| Viatris Specialty LLC | $16.71 | 2025 | Yupelri |
| Pfizer INC. | $16.05 | 2023 | |
| Hikma Pharmaceuticals USA | $15.80 | 2024 | Ryaltris |
| Lundbeck LLC | $15.23 | 2021 | |
| Aimmune Therapeutics, INC. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.